Back to Search Start Over

Hippocampal overexpression of NOS1AP promotes endophenotypes related to mental disorders.

Authors :
Freudenberg F
Candemir E
Chen X
Li LL
Esen-Sehir D
Schenk N
Kinoshita M
Grünewald L
Frerichs V
Fattakhov N
Manchen J
Bikas S
Kumar A
OLeary A
Slattery DA
von Engelhardt J
Courtney MJ
Reif A
Source :
EBioMedicine [EBioMedicine] 2021 Sep; Vol. 71, pp. 103565. Date of Electronic Publication: 2021 Aug 27.
Publication Year :
2021

Abstract

Background: Nitric oxide synthase 1 adaptor protein (NOS1AP; previously named CAPON) is linked to the glutamatergic postsynaptic density through interaction with neuronal nitric oxide synthase (nNOS). NOS1AP and its interaction with nNOS have been associated with several mental disorders. Despite the high levels of NOS1AP expression in the hippocampus and the relevance of this brain region in glutamatergic signalling as well as mental disorders, a potential role of hippocampal NOS1AP in the pathophysiology of these disorders has not been investigated yet.<br />Methods: To uncover the function of NOS1AP in hippocampus, we made use of recombinant adeno-associated viruses to overexpress murine full-length NOS1AP or the NOS1AP carboxyterminus in the hippocampus of mice. We investigated these mice for changes in gene expression, neuronal morphology, and relevant behavioural phenotypes.<br />Findings: We found that hippocampal overexpression of NOS1AP markedly increased the interaction of nNOS with PSD-95, reduced dendritic spine density, and changed dendritic spine morphology at CA1 synapses. At the behavioural level, we observed an impairment in social memory and decreased spatial working memory capacity.<br />Interpretation: Our data provide a mechanistic explanation for a highly selective and specific contribution of hippocampal NOS1AP and its interaction with the glutamatergic postsynaptic density to cross-disorder pathophysiology. Our findings allude to therapeutic relevance due to the druggability of this molecule.<br />Funding: This study was funded in part by the DFG, the BMBF, the Academy of Finland, the NIH, the Japanese Society of Clinical Neuropsychopharmacology, the Ministry of Education of the Russian Federation, and the European Community.<br />Competing Interests: Declaration of competing interest Andreas Reif received speaker's honoraria from Janssen, Medice, Shire/Takeda, Servier and neuraxpharm, is on the Advisory boards for Janssen, Medice, Shire/Takeda and SAGE and received grant support from Medice. None of these relationships are directly related to the study reported herein. All other authors report no financial relationships with commercial interests.<br /> (Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
2352-3964
Volume :
71
Database :
MEDLINE
Journal :
EBioMedicine
Publication Type :
Academic Journal
Accession number :
34455393
Full Text :
https://doi.org/10.1016/j.ebiom.2021.103565